SEC Filing Summary: 180 Life Sciences Corp. (ATNF)
Business Context and Reporting Period
This Form 8-K Current Report, dated February 16, 2024, covers events occurring at a Special Meeting of stockholders for 180 Life Sciences Corp. (Note: The request metadata referenced "FORUM MARKETS Inc," but the filing text explicitly identifies the registrant as 180 Life Sciences Corp.). The report details the approval of corporate governance amendments, a reverse stock split, and the issuance of warrants.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
Stockholders approved four key proposals at the Special Meeting:
- Reverse Stock Split: Approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock by a ratio between 1-for-4 and 1-for-40. The exact ratio is to be determined by the Board of Directors prior to February 16, 2025.
- Incentive Plan Amendment: Approved the Second Amendment to the 2022 Omnibus Incentive Plan (OIP), increasing the maximum number of shares available for issuance from 470,000 to 4,249,933 shares.
- Warrant Issuance: Approved the issuance of shares upon the exercise of pre-funded warrants (4,886,878 shares at $0.0001) and warrants (18,128,196 shares at $0.17) at a price below the Nasdaq Minimum Price. As a result of this approval, the Warrants are now exercisable.
- Adjournment: Approved the ability to adjourn the meeting to solicit additional proxies, though this had no effect as the primary proposals were approved.
Voting Results
| Proposal | For | Against | Abstentions | Broker Non-Votes | Result |
|---|---|---|---|---|---|
| Reverse Stock Split (1-4 to 1-40) | 3,662,372 | 653,782 | 3,554 | — | Approved |
| OIP Amendment | 531,011 | 256,738 | 4,263 | 792,012 | Approved (~67.0%) |
| Warrant Issuance | 611,576 | 175,457 | 4,979 | 792,012 | Approved (~77.2%) |
| Adjournment | 3,762,247 | 552,370 | 5,091 | — | Approved (No Effect) |
Outlook, Risks, and Contingencies
The filing notes that the Warrants are now exercisable following stockholder approval. The reverse stock split ratio remains a contingency to be determined by the Board within the next year. No specific forward-looking financial guidance or management commentary on operational risks is included in this specific filing.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once announced by the Board of Directors (deadline: Feb 16, 2025).
- Monitor the exercise of the newly approved warrants (4.9M pre-funded and 18.1M standard warrants) for potential dilution impact.
- Review the full text of the Second Amended and Restated 2022 Omnibus Incentive Plan (Exhibit 10.2) for specific terms regarding the increased share pool.
- Confirm the company's compliance with Nasdaq listing rules following the reverse stock split and warrant issuance.